Author

A. Zauberman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 4 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Y. Levy· 5 shared D. Gur· 4 shared E. Epstein· 4 shared E. Makdasi· 4 shared M. Aftalion· 4 shared O. Mazor· 4 shared R. Alcalay· 4 shared R. Rosenfeld· 4 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

Y. Levy

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Phage therapy potentiates second-line antibiotic treatment against pneumonic plague

Y. Vagima, D. Gur, M. Aftalion, S. Moses, Y. Levy, A. Makovitzki, T. Holtzman, Z. Oren, Y. Segula, E. Fatelevich, A. Tidhar, A. Zauberman, S. Rotem, E. Mamroud, I. Steinberger-Levy

This paper shows that combining phage therapy with ceftriaxone improves survival in a mouse model of pneumonic plague caused by multidrug-resistant Yersinia pestis.

bioRxiv · Feb 7, 2022Microbiology

Fc-independent neutralization of SARS-CoV-2 by recombinant human monoclonal antibodies

T. Noy-Porat, A. Edri, R. Alcalay, E. Makdasi, D. Gur, M. Aftalion, Y. Evgy, A. Beth-Din, Y. Levy, E. Epstein, O. Radinsky, A. Zauberman, S. Lazar, S. Yitzhaki, H. Marcus, , O. Mazor

This study shows that Fc-independent monoclonal antibodies can neutralize SARS-CoV-2 in mice, reducing viral load and preventing mortality without Fc-dependent effector functions.

bioRxiv · May 15, 2021Immunology

Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice

T. Noy-Porat, A. Mechaly, Y. Levy, E. Makdasi, R. Alcalay, D. Gur, M. Aftalion, R. Falach, S. Leviatan Ben-Arye, S. Lazar, A. Zauberman, E. Epstein, T. Chitlaru, S. Weiss, H. Achdout, , R. Rosenfeld

This study identifies and characterizes neutralizing antibodies targeting the SARS-CoV-2 spike N-terminal domain, showing their protective efficacy in mice.

bioRxiv · Feb 2, 2021Immunology

Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody

R. Rosenfeld, T. Noy-Porat, A. Mechaly, E. Makdasi, Y. Levy, R. Alcalay, R. Falach, M. Aftalion, E. Epstein, D. Gur, T. Chitlaru, E. B. Vitner, S. Melamed, B. Politi, A. Zauberman, , O. Mazor

This study shows that the human monoclonal antibody MD65 can rescue 100% of SARS-CoV-2 infected mice when administered up to 3 days post-exposure.

bioRxiv · Oct 26, 2020Immunology

Tiger team: a panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

T. Noy-Porat, E. Makdasi, R. Alcalay, A. Mechaly, Y. Levy, A. Bercovich-Kinori, A. Zauberman, H. Tamir, Y. Yahalom-Ronen, M. Israeli, E. Epstein, H. Achdout, S. Melamed, T. Chitlaru, S. Weiss, , R. Rosenfeld

This paper isolates and characterizes a panel of human neutralizing monoclonal antibodies targeting SARS-CoV-2 spike at multiple epitopes, suggesting their potential for combined post-exposure therapy.

bioRxiv · May 20, 2020Immunology